Oral Decitabine Plus Cedazuridine and Venetoclax for Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukaemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
Lancet Haematol 2024 Feb 02;[EPub Ahead of Print], A Bataller, G Montalban-Bravo, A Bazinet, Y Alvarado, K Chien, S Venugopal, J Ishizawa, D Hammond, M Swaminathan, K Sasaki, GC Issa, NJ Short, L Masarova, NG Daver, TM Kadia, S Colla, W Qiao, X Huang, R Kanagal-Shamanna, S Hendrickson, F Ravandi, E Jabbour, H Kantarjian, G Garcia-ManeroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.